Log In
BCIQ
Print this Print this
 

tezepelumab (AMG 157, MEDI9929)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb that blocks interaction of thymic stromal lymphopoietin (TSLP) with the TSLP receptor
Molecular Target Thymic stromal lymphopoietin (TSLP)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$50.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/02/2012

Undisclosed

$50.0M

0

Get a free BioCentury trial today